NCT04772235CompletedPhase 1
Phase I Clinical Study to Assess Safety and Efficacy of Repotrectinib Combined with Osimertinib in Patients with Advanced, Metastatic EGFR Mutant NSCLC (TOTEM).
Source: EU CTIS (euclinicaltrials.eu) · Last updated 23 Jul 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- First submitted
- 17 Jul 2024
- Start date
- 30 Jun 2021
- Lead sponsor
- Instituto Oncologico Dr. Rosell S.L.
- Diseases
- Lung cancer
- NCT number
- NCT04772235
- EU CT number
- 2023-509776-41-00
- EudraCT number
- 2020-005151-20
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 48
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitari Dexeus Grupo Quironsalud Coordinator of this site? Confirm its status | Barcelona | Spain | Completed |
| Hospital General Universitario Gregorio Marañón Coordinator of this site? Confirm its status | Madrid | Spain | Completed |
| Hospital Universitario Regional de Málaga Coordinator of this site? Confirm its status | Málaga | Spain | Completed |
| University Hospital Son Espases Coordinator of this site? Confirm its status | Palma | Spain | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.